[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Luque-Cabal et al., 2016 - Google Patents

Mechanisms behind the resistance to trastuzumab in HER2-amplified breast cancer and strategies to overcome it

Luque-Cabal et al., 2016

View HTML
Document ID
16303215565445851295
Author
Luque-Cabal M
García-Teijido P
Fernández-Pérez Y
Sánchez-Lorenzo L
Palacio-Vázquez I
Publication year
Publication venue
Clinical Medicine Insights: Oncology

External Links

Snippet

The introduction of trastuzumab therapy markedly improved the poor prognosis associated with HER2-amplified breast cancers. Despite this, the presence of primary and acquired resistance to trastuzumab treatment remains a significant common challenge. The …
Continue reading at journals.sagepub.com (HTML) (other versions)

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay
    • G01N33/574Immunoassay; Biospecific binding assay for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57415Specifically defined cancers of breast
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Hybridisation probes
    • C12Q1/6883Hybridisation probes for diseases caused by alterations of genetic material
    • C12Q1/6886Hybridisation probes for diseases caused by alterations of genetic material for cancer

Similar Documents

Publication Publication Date Title
Luque-Cabal et al. Mechanisms behind the resistance to trastuzumab in HER2-amplified breast cancer and strategies to overcome it
Pernas et al. HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance
Majewski et al. PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2–targeted therapies in breast cancer
Iqbal et al. Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications
Loree et al. Recent developments in the treatment of metastatic colorectal cancer
Tagliabue et al. HER2 as a target for breast cancer therapy
Millis et al. Landscape of phosphatidylinositol-3-kinase pathway alterations across 19 784 diverse solid tumors
Gavin et al. Association of polymorphisms in FCGR2A and FCGR3A with degree of trastuzumab benefit in the adjuvant treatment of ERBB2/HER2–positive breast cancer: analysis of the NSABP B-31 trial
Qu et al. The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer
Mukohara Mechanisms of resistance to anti‐human epidermal growth factor receptor 2 agents in breast cancer
Fiszman et al. Molecular mechanisms of trastuzumab resistance in HER2 overexpressing breast cancer
Spector et al. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2–positive breast cancer
Crimini et al. Precision medicine in breast cancer: From clinical trials to clinical practice
Nahta et al. Trastuzumab: triumphs and tribulations
Nahta Molecular mechanisms of trastuzumab‐based treatment in HER2‐overexpressing breast cancer
Zhang et al. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor–expressing metastatic colorectal cancer patients treated with single-agent cetuximab
Nahta et al. HER-2-targeted therapy: lessons learned and future directions
Rimawi et al. Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2–overexpressing breast cancer: TBCRC 006
Stern Improving treatment of HER2-positive cancers: opportunities and challenges
Gunturu et al. Gastric cancer and trastuzumab: first biologic therapy in gastric cancer
Hecht et al. Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer
Tobin et al. The importance of molecular markers for diagnosis and selection of targeted treatments in patients with cancer
Okines et al. Trastuzumab: a novel standard option for patients with HER-2-positive advanced gastric or gastro-oesophageal junction cancer
La Salvia et al. HER2-targeted therapy: an emerging strategy in advanced colorectal cancer
Wahdan-Alaswad et al. Targeted lapatinib anti-HER2/ErbB2 therapy resistance in breast cancer: Opportunities to overcome a difficult problem